Cytek Biosciences, Inc. (CTKB) Revenue History
Cytek Biosciences, Inc. (CTKB) annual revenue history. Get revenue data in Excel with MarketXLS.
Revenue Data
| Period | Revenue (USD) |
|---|---|
| 2021-12-31 | $127.95M |
| 2022-12-31 | $164.04M |
| 2023-12-31 | $193.01M |
| 2024-12-31 | $200.45M |
| 2025-12-31 | $201.49M |
How CTKB compares with sector peers
| Symbol | Company | Revenue (latest fiscal year) |
|---|---|---|
| AKBA | Akebia Therapeutics Inc. | $236.20M |
| CERS | Cerus Corporation | $233.80M |
| AXGN | Axogen Inc. | $225.21M |
| VNDA | Vanda Pharmaceuticals Inc. | $216.10M |
| SNDX | Syndax Pharmaceuticals Inc. | $172.35M |
These are five companies in the same sector as CTKB with a comparable annual revenue. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Cytek Biosciences, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue("CTKB", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | CTKB | $4.68 | +1.30% | 0.80M |
| 3 | ||||
| 4 | ||||
| 5 |